The likelihood of a large-scale collapse of the batch is likely to decrease

It's unlikely that the batch will go out of business on a large scale! The number may decrease, but is mainly consolidated and annexed.the collapse of the pharmaceutical batch, it is unlikely
2016 circulation rectification, 2017 two-vote system, two years, the pharmaceutical circulation industry by the policy frequently "shock". In January 2017, the State Office's Opinions on Further Reforming and Perfecting the Policy on the Circulation and Use of Pharmaceutical Production and Distribution injected the will of the state into the industry - the strong and the weak died.
"the large-scale closure of small and medium-sized drug batches, is a big probability event, " many people said.
year has passed, according to previous speculation, the collapse of the drug batch of the remains tired, I am afraid that many prophets can support the peak of life. Is that really the case? Recently, the author interviewed dozens of industry veterans from industrial, commercial and retail terminals.
comprehensive interview information, concluded that is the opening sentence: the large-scale closure of the drug batch, it is unlikely.number of drug companies is increasing, resulting in a two-vote system
a senior official of a pharmaceutical company in Jilin told the author, "Now the drug circulation enterprises, are still alive." Only before relying on the reverse ticket, over the ticket of the enterprise has not been alive, but the normal operation of the enterprise, are no matter. In addition, some small companies, have been acquired by large companies, future mergers and acquisitions are mainstream. This
also confirmed by the authoritative statistics of these countries.
June 21, the Ministry of Commerce released the "2017 Drug Circulation Industry Operation Statistics Analysis Report" shows that as of the end of 2017, there were 13,146 pharmaceutical wholesale enterprises nationwide, compared with the 2016 Ministry of Commerce analysis report data, the number of drug batches increased by 171.
number of people is actually increasing.
, the head of a commercial company in Shandong said that in the past year due to the two-vote system, the transfer between group companies to calculate a vote. Many large pharmaceutical companies build or acquire pharmaceutical companies as subsidiaries in various places. This brings up the number of commercial companies and the overall growth figures.Sm. small and medium-sized drug batch has no chance, the acquisition, integration is fatal
" drug batch closure is impossible, it is really not good to operate, but also asset mergers and acquisitions, shell license plate is also valuable, " said a senior person in Shanghai.
Failure is not so easy, now control fees, health care funding shortage, drug production over-production capacity, consistent evaluation, the capital chain is certainly tight, these small businesses are difficult to adhere to, only with large enterprises tied together.
just want to live, often have to come up with their own core things - local channels and distribution rights, access to space for existence.
when the author to each interviewee "small and medium-sized medicine batch still have a chance" question, the answer is no surprise is "no!" "
State-controlled China Resources on drugs, Kyushua Tong and other leading, small companies characteristics of the operation of
" is not said to be acquired, and now and large enterprises to take cooperation with those companies, may be able to support a period of time, in the long run, the final result is either swallowed or used to throw away like waste. "One respondent who is currently working with a large company said.
"Is there a bigger advantage than money now?" Large enterprises have guaranteed capital, supply chain has advantages, this is real. "
small and medium-sized drug batch can not avoid the integration, acquisition of the outcome. The future pattern, the state-controlled China Resources on medicine, Kyushu Tongnan medicine, guang medicine, ha medicine, Colum and other leading, coupled with some small companies characteristics of the operation, this is the case. (Seber Blue)